MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Medpace Holdings Inc

Gesloten

SectorGezondheidszorg

303.85 -2.11

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

297.03

Max

310.51

Belangrijke statistieken

By Trading Economics

Inkomsten

21M

117M

Verkoop

3.3M

537M

K/W

Sectorgemiddelde

24.105

63.778

EPS

3.681

Winstmarge

21.808

Werknemers

5,900

EBITDA

-916K

125M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+11.39% upside

Dividenden

By Dow Jones

Volgende Winsten

21 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

9.5B

Vorige openingsprijs

305.96

Vorige sluitingsprijs

303.85

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Medpace Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 apr 2025, 23:04 UTC

Top Nieuws

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 apr 2025, 22:40 UTC

Belangrijke Marktbewegers

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 apr 2025, 22:18 UTC

Acquisities, Fusies, Overnames

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 apr 2025, 18:51 UTC

Acquisities, Fusies, Overnames

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 apr 2025, 23:43 UTC

Marktinformatie

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 apr 2025, 23:41 UTC

Marktinformatie

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 apr 2025, 22:22 UTC

Acquisities, Fusies, Overnames

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr 2025, 22:21 UTC

Acquisities, Fusies, Overnames

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr 2025, 21:43 UTC

Top Nieuws
Winsten

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 apr 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

3 apr 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

3 apr 2025, 20:43 UTC

Marktinformatie

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 apr 2025, 20:34 UTC

Top Nieuws

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 apr 2025, 20:23 UTC

Top Nieuws

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 apr 2025, 20:15 UTC

Acquisities, Fusies, Overnames

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 apr 2025, 19:55 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 apr 2025, 19:55 UTC

Marktinformatie

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 apr 2025, 19:21 UTC

Marktinformatie

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 apr 2025, 19:15 UTC

Marktinformatie

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 apr 2025, 18:45 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

3 apr 2025, 18:45 UTC

Marktinformatie

Gold Drops In Tariff Fallout -- Market Talk

3 apr 2025, 18:39 UTC

Marktinformatie

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 apr 2025, 18:38 UTC

Top Nieuws

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 apr 2025, 18:30 UTC

Top Nieuws

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 apr 2025, 18:20 UTC

Marktinformatie

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 apr 2025, 18:18 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

3 apr 2025, 18:17 UTC

Marktinformatie

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 apr 2025, 18:04 UTC

Marktinformatie

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 apr 2025, 17:55 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Medpace Holdings Inc Prognose

Koersdoel

By TipRanks

11.39% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 346.67 USD  11.39%

Hoogste 370 USD

Laagste 330 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Medpace Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

2

Buy

3

Hold

0

Sell

Technische score

By Trading Central

295.43 / 321.12Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Medpace Holdings Inc

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.